Health Care & Life Sciences » Biotechnology | Voyager Therapeutics Inc.

Voyager Therapeutics Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
-
-
17,334.00
14,220.00
10,135.00
7,619
Cost of Goods Sold (COGS) incl. D&A
-
184.00
-
-
-
-
Gross Income
-
184.00
-
-
-
-
SG&A Expense
3,766.00
14,183.00
36,988.00
54,907.00
80,403.00
96,597
EBIT
3,766.00
14,367.00
20,254.00
41,299.00
71,863.00
91,095
Unusual Expense
-
-
9,750.00
-
-
-
Non Operating Income/Expense
-
-
-
182.00
62.00
683
Interest Expense
67.00
1,950.00
-
-
-
-
Pretax Income
3,833.00
16,317.00
29,672.00
40,141.00
70,698.00
88,468
Income Tax
-
-
-
52.00
-
180
Consolidated Net Income
3,833.00
16,317.00
29,672.00
40,193.00
70,698.00
88,288
Net Income
3,833.00
16,317.00
29,672.00
40,193.00
70,698.00
88,288
Net Income After Extraordinaries
3,833.00
16,317.00
29,672.00
40,193.00
70,698.00
88,288
Net Income Available to Common
3,833.00
17,683.00
38,290.00
40,193.00
70,698.00
88,288
EPS (Basic)
0.14
0.66
9.14
1.59
2.64
2.75
Basic Shares Outstanding
26,784.70
26,784.70
4,191.20
25,302.40
26,803.70
32,065.80
EPS (Diluted)
0.14
0.66
9.14
1.59
2.64
2.75
Diluted Shares Outstanding
26,784.70
26,784.70
4,191.20
25,302.40
26,803.70
32,065.80
EBITDA
3,766.00
14,183.00
19,654.00
40,687.00
70,268.00
88,978
Non-Operating Interest Income
-
-
332.00
976.00
1,227.00
3,310
Preferred Dividends
-
1,366.00
8,618.00
-
-
-

About Voyager Therapeutics

View Profile
Address
75 Sidney Street
Cambridge Massachusetts 02139
United States
Employees -
Website http://www.voyagertherapeutics.com
Updated 07/08/2019
Voyager Therapeutics, Inc. is a clinical-stage gene therapy company, which develops treatments for patients suffering from central nervous system. Its pipeline of gene theraphy programs include VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01. The company was founded by Guangping Gao, Mark A.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.